References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailAssociation of Tibolone and Fluoride Displays a Pronounced Effect on Bone Mineral Density in Postmenopausal Osteoporotic Women
Reginster, Jean-Yves ULg; Agnusdei, D.; Gennari, C. et al

in Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology (1999), 13(5), 361-8

A double-blind, placebo-controlled, randomized, prospective two-center study was carried out to assess the effects of tibolone + fluoride versus placebo + fluoride therapy on trabecular and cortical bone ... [more ▼]

A double-blind, placebo-controlled, randomized, prospective two-center study was carried out to assess the effects of tibolone + fluoride versus placebo + fluoride therapy on trabecular and cortical bone in postmenopausal osteoporotic women. Ninety-four subjects (mean age 61.1 years, postmenopausal 13.5 years on average) with low bone mineral density (BMD) at baseline were randomized to 2.5 mg of tibolone (Org OD 14, Livial) plus 26.4 mg of fluoride (Fluocalcic) or placebo plus 26.4 mg of fluoride daily over 2 years; 55 (58.5%) subjects completed the study, the main reason for discontinuation being untoward gastrointestinal effects. BMD at the lumbar spine was measured by both dual photon absorptiometry (DPA) and dual-energy X-ray absorptiometry (DXA), and at the hip by DXA at 6-month intervals. Baseline values (DXA, g/cm2) for tibolone + fluoride and placebo + fluoride groups were 0.733 and 0.744 for the lumbar spine, and 0.761 and 0.788 for the hip. Change from baseline and percentage change from baseline were calculated for the intent-to-treat and completers groups. An analysis of variance (ANOVA) model or Wilcoxon test was used for statistical evaluation. There was a mean increase in BMD at the lumbar spine measured by DPA of 25.3% and 12.3% in tibolone + fluoride and placebo + fluoride groups, respectively (p = 0.01); with DXA, respective changes were 32.6% and 14.0% (p = 0.013). Data on BMD at the hip showed mean increases of 7.9% and 2.6% for the tibolone + fluoride and placebo + fluoride groups, respectively. We conclude that combined tibolone + fluoride treatment induces a highly significant increase in BMD at the lumbar spine without simultaneous loss of the cortical bone allowing for a meaningful reduction of the fluoride dose when given in combination with tibolone. [less ▲]

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailAlphacalcidol in Prevention of Glucocorticoid-Induced Osteoporosis
Reginster, Jean-Yves ULg; de Froidmont, C.; Lecart, M. P. et al

in Calcified Tissue International (1999), 65(4), 328-31

One of the major drawbacks of glucocorticoids long-term therapy is the occurrence of a severe osteoporosis characterized by fractures occurring at different sites, mainly at the level of trabecular bone ... [more ▼]

One of the major drawbacks of glucocorticoids long-term therapy is the occurrence of a severe osteoporosis characterized by fractures occurring at different sites, mainly at the level of trabecular bone. One of the major determinants of glucocorticoid-induced osteoporosis is a decrease in the intestinal absorption of calcium (Ca) leading to a secondary hyperparathyroidism. D-hormones have been shown to significantly improve Ca absorption in the gut and subsequently to decrease parathyroid hormone circulating levels, hence normalizing bone turnover. In a recent study evaluating 145 patients suffering from diseases requiring long-term treatment with high doses of corticosteroids, we have demonstrated a significant benefit of alphacalcidol (1 microg/day) over placebo in terms of changes in bone mineral density of the lumbar spine. These results are in accordance with studies showing better prevention of bone loss and vertebral fractures in cardiac transplant patients treated with alphacalcidol than those treated with etidronate. There is now a convergent body of evidence to suggest that alphacalcidol is a reasonable, safe, and effective option for the prevention of glucocorticoid-induced osteoporosis, provided that serum Ca is monitored on a regular basis. [less ▲]

Detailed reference viewed: 17 (2 ULg)
Peer Reviewed
See detailComparative effects of nimesulide, nimesulide L-lysine and nimesulide L-lysine L-arginine on human articular chondrocytes in vitro
De Leval, X.; Dogne, J. M.; Delarge, J. et al

Poster (1999, September 17)

Detailed reference viewed: 13 (6 ULg)
Peer Reviewed
See detailSynthesis and evaluation of non-carboxylic pyridinic derivatives as cyclooxygenase inhibitors
Dogne, J. M.; De Leval, X.; Delarge, J. et al

Poster (1999, September 17)

Detailed reference viewed: 12 (7 ULg)
Peer Reviewed
See detailEvaluation de la sélectivité COX-1 vs COX-2 de drogues à potentialités anti-inflammatoires
De Leval, X.; Dogne, J. M.; Neven, Ph. et al

Poster (1999, May)

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailAnabolic Events in Osteoarthritis
Henrotin, Yves ULg; Reginster, Jean-Yves ULg

in Osteoarthritis and Cartilage (1999), 7(3), 310-2

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailIn-Vitro Differences among Nonsteroidal Antiinflammatory Drugs in Their Activities Related to Osteoarthritis Pathophysiology
Henroitin, Y.; Reginster, Jean-Yves ULg

in Osteoarthritis and Cartilage (1999), 7(3), 355-7

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailL'ostéoporose d'involution chez la femme
Reginster, Jean-Yves ULg; Devogelaer, J. P.; Kaufman, J. M. et al

in Revue Médicale de Liège (1999), 54(4), 335-40

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches ... [more ▼]

Postmenopausal osteoporosis is now considered a major public health problem in aging women, due to the burden related to the consequent fractures. Over recent years, several pharmacological approaches were developed for the prevention and treatment of osteoporosis. Besides regular physical exercise and calcium rich diet, calcium supplementation can be suggested to both genders, after seventy years as well as systematic vitamin D supplementation in order to cope with the frequent lack observed in our country. Hormone replacement therapy is the first choice in prevention of postmenopausal osteoporosis. Based on a careful evaluation of the needs of a postmenopausal woman as well as on the risk/benefit ratio derived from her individual risk factors, selective estrogen receptor modulators (raloxifene) or second generation bisphosphonates (alendronate) can be considered as alternative to estrogens. Due to its prohibitive cost, nasal calcitonin should be only considered for very specific cases. In osteoporosis confirmed by bone densitometry or by occurrence of fractures, bisphosphonate (alendronate) reduces subsequent fracture rate. Fluoride salts can, in some cases, improve spinal symptomatic osteoporosis. The use of etidronate, a molecule from the past, should be avoided as much as possible and, at any rate, strictly restricted to its legal indication including women with several vertebral crush fractures and severely decreased bone mineral density. [less ▲]

Detailed reference viewed: 45 (3 ULg)
Full Text
Peer Reviewed
See detailComment j'explore ... l'ostéoporose: mesure de la masse osseuse et analyses biologiques
Reginster, Jean-Yves ULg; Devogelaer, J. P.; Kaufman, J. M. et al

in Revue Médicale de Liège (1999), 54(3), 184-8

The use of bone densitometry, by dual energy x-ray absorptiometry, allows the identification, at an early stage, of subjects who will, 15-20 years later, present a fracture event. Furthermore, this ... [more ▼]

The use of bone densitometry, by dual energy x-ray absorptiometry, allows the identification, at an early stage, of subjects who will, 15-20 years later, present a fracture event. Furthermore, this technique is the most appropriate to confirm the efficacy of preventive or curative therapeutic approaches of osteoporosis. A balanced utilisation of biochemical tests is mandatory to exclude a secondary cause of osteoporosis, to help in the choice of the most appropriate therapeutic strategy and to evaluate the early response of patients to the administered drugs. [less ▲]

Detailed reference viewed: 20 (3 ULg)
Peer Reviewed
See detailPromising New Agents in Osteoporosis
Reginster, Jean-Yves ULg; Henrotin, Yves ULg; Gosset, Christiane ULg

in Drugs in R&D (1999), 1(3), 195-201

Currently marketed inhibitors of bone resorption or stimulators of bone formation have significantly contributed to a better preventive and therapeutic approach to postmenopausal and senile osteoporosis ... [more ▼]

Currently marketed inhibitors of bone resorption or stimulators of bone formation have significantly contributed to a better preventive and therapeutic approach to postmenopausal and senile osteoporosis. However, none of the available compounds has unequivocally demonstrated an ability to fully prevent the occurrence of new vertebral or peripheral osteoporotic fractures once the disease is established. Therefore, several new medications are being developed, with the aim of providing a better risk-benefit profile and/or a more favourable cost-utility assessment than available drugs. Potential inhibitors of bone resorption include specific inhibitors of the osteoclast's proton pump, inhibitors of prostaglandins or nitric oxide donors. Stimulators of osteoblastic activity and subsequent bone formation might be obtained by strontium salts, peptides of the parathyroid hormone family, growth hormone and insulin-like growth factors or bone morphogenetic proteins. Most of these compounds are now undergoing phase II/III development programmes, and results evaluating their potential benefit should be available within 1 to 5 years. [less ▲]

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailMorphometrical study of the equine navicular bone: age-related changes and influence of exercise
Gabriel, Annick ULg; Detilleux, Johann ULg; Jolly, Sandra ULg et al

in Veterinary Research Communications (1999), 23(1), 15-40

Navicular bones from the four limbs of 95 horses, classified in 9 categories, were studied. The effects of age on navicular bone morphometry and histomorphometry were estimated, after adjustment of the ... [more ▼]

Navicular bones from the four limbs of 95 horses, classified in 9 categories, were studied. The effects of age on navicular bone morphometry and histomorphometry were estimated, after adjustment of the data to even out the effects of front and rear limbs, morphometrical type, sex, weight, and size. All the external measurements of the navicular bone decreased significantly with increasing age. From the histomorphometrical data, cortical bone volume decreased with age in most horses, whereas cancellous bone volume and, in particular, the marrow spaces increased. The increase in the cancellous bone volume could have resulted from tunnelling of the internal part of the cortex, which converted it progressively into a porous trabecular-like structure. Trabecular bone volume also decreased with age and the trabecular lattice changed dramatically to become disconnected in aged horses. These observations corresponded closely to those reported for ageing of the skeletal system in humans. However, in sporting horses, the navicular cortical bone volume increased with age and the cancellous bone volume decreased. Exercise appeared to have decreased bone resorption and increased bone formation at the endocortical junction. The cancellous bone architecture was also improved. in that the trabecular lattice and trabecular bone volume remained unchanged in aged sporting horses. Our findings confirmed that exercise may be good practice to prevent age-related bone loss. [less ▲]

Detailed reference viewed: 37 (9 ULg)
Full Text
See detailRecommandations for Health Economics Evaluations of interventions in Osteoporosis
Reginster, Jean-Yves ULg; Gathon, Henry-Jean ULg; Marciniak, A. et al

Book published by World Health Organization (1999)

Detailed reference viewed: 14 (10 ULg)
Full Text
Peer Reviewed
See detailLimited clinical utility of a self-evaluating risk assessment scale for postmenopausal osteoporosis: lack of predictive value of lifestyle-related factors
Goemaere, S; Zegels, Brigitte ULg; Toye, K et al

in Calcified Tissue International (1999), 65(5), 354-358

The aim of this study was to assess the efficiency of a self-administered questionnaire to identify subjects with postmenopausal osteoporosis in the setting of first line medical care. A sample of 300 ... [more ▼]

The aim of this study was to assess the efficiency of a self-administered questionnaire to identify subjects with postmenopausal osteoporosis in the setting of first line medical care. A sample of 300 postmenopausal women completed the questionnaire based on 18 items. Bone mineral density at the lumbar spine (BMD-L), total hip (BMD-H), and femoral neck (BMD-N) was used as objective criterion for evaluation. The mean risk score was 8.2 +/- 3.21. BMD was correlated with total risk score: r = -0.32 for BMD-L, -0.36 for BMD-N, and -0.43 for BMD-H. Cutoff points for the risk score (equal likelihood points) according to a T-score threshold of -2.5 were 8.6 for BMD-L and BMD-N and 9.3 for BMD-H; specificity and sensitivity was 62% and 62%, respectively, for BMD-L, 65% and 62% for BMD-N, and 75% and 63% for BMD-H. Stepwise multiple regression analysis of the questionnaire items in relation to BMD showed higher correlation coefficients for models including individual items rather than the overall risk score. Items concerning low weight, older age, and wrist fracture after 50 years of age were always selected as significant determinants of BMD (R = 0.43-0.55). Hormonal replacement therapy was also an important determinant. Lifestyle-related items did not contribute significantly. In conclusion, the diagnostic performance of the 18-item self-administered questionnaire was poorer than a shortened questionnaire omitting lifestyle factors. The clinical utility of a questionnaire should ultimately be evaluated in the specific optic of a chosen global strategy for prevention of osteoporotic fractures. [less ▲]

Detailed reference viewed: 16 (7 ULg)
Full Text
Peer Reviewed
See detailHigh Prevalence of Low Femoral Bone Mineral Density in Elderly Women Living in Nursing Homes or Community-Dwelling: A Plausible Role of Increased Parathyroid Hormone Secretion
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Pirenne, H. et al

in Osteoporosis International (1999), 9(2), 121-8

The present study was designed to visit elderly women living in nursing homes and to compare their femoral neck bone mineral density (BMD) and circulating levels of parathyroid hormone (PTH) and 25-OH ... [more ▼]

The present study was designed to visit elderly women living in nursing homes and to compare their femoral neck bone mineral density (BMD) and circulating levels of parathyroid hormone (PTH) and 25-OH vitamin D (25-OHD) with those of subjects living at home, in the immediate vicinity of the nursing homes. Of 1483 women, aged 70 years and older, who were selected, 993 agreed to participate in this trial. Their femoral neck BMD (n = 993) was measured by dual-energy X-ray absorptiometry, with a specific device installed in a mobile truck. The circulating levels of 25-OHD and PTH were assessed after an overnight fast (n = 748). After stratification for age, there were no significant differences in mean femoral neck BMD values, prevalence of femoral neck osteoporosis, mean serum 25-OHD and prevalence of absolute or relative 25-OHD deficiency between the two groups. Serum levels of PTH were significantly higher in women over 80 years old living in nursing homes, compared with the community-dwelling women. After adjustment for age, a significant relation was found between femoral neck BMD and PTH levels in the whole population (p = 0.004) and in community-dwelling subjects (p = 0.039). When stratifying our population by quartiles of serum PTH values, the odds ratios for femoral neck osteoporosis were significantly increased for the top two quartiles compared with the lowest one both before (p = 0.00146) and after (p = 0.0013) adjustment for age and type of housing. From this study we conclude that femoral osteoporosis is largely underestimated in European women. Living in a nursing home is not, per se, a risk factor for decreased femoral BMD, and circulating PTH levels are a key determinant of low femoral bone density and osteoporosis. [less ▲]

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailIncreased number of hip fractures.
Gillet, Pierre ULg; Reginster, Jean-Yves ULg

in Lancet (1999), 353(9170), 2160-1

Detailed reference viewed: 11 (4 ULg)
Full Text
Peer Reviewed
See detailBisphosphonates in the prevention and treatment of osteoporosis : state of the art
Reginster, Jean-Yves ULg

in Climacteric : The Journal of the International Menopause Society (1999), 2(S12-5), 43

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailPrévention de la perte osseuse postménopausique par strontium ranelate
Roux, C; Dougados, M; Reginster, Jean-Yves ULg et al

in Revue du Rhumatisme (1999), 1bis

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailL’ostéoporose chez la personne âgée
Reginster, Jean-Yves ULg; Taquet, AN; Fraikin, G

in Medi-Sphere (1999), 103

Detailed reference viewed: 13 (5 ULg)
Peer Reviewed
See detailCalcitonine dans la prévention secondaire et tertiaire de l’ostéoporose
Halkin, V; Reginster, Jean-Yves ULg

in Medi-Sphere (1999), 3

Detailed reference viewed: 12 (2 ULg)
Peer Reviewed
See detailAdvocado/soybean unsaponifiable mixture increased high molecular weight proteoglycans synthesis by human articular chondrocytes
Henrotin, Yves ULg; Labasse, A; Guillou, B et al

in Annals of Rheumatoid Arthritis (1999), 230

Detailed reference viewed: 18 (3 ULg)